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Abstract: B a c k g r o u n d a n d s t u d y a im s: The aim of the study was to assess the usefulness of
serum concentrations of YKL-40/ CHI3L1 (a 40-kilodalton glycoprotein also referred to as chitinase 3 like-
1 — CHI3L1) and PIIINP (N-terminal propeptide of type III procollagen), markers of fibrosis, in the
monitoring of inflammatory processes and fibrosis in children with inflammatory bowel disease (IBD).
P a t i e n t s a n d m e t h o d s: In 60 patients (41 with Crohn’s disease (CD), 19 with ulcerative colitis (UC))
concentrations of investigated parameters were measured at baseline (day 0), after 3 and after 6–8 weeks
of pharmacological treatment.
R e s u l t s: PIIINP concentrations were significantly higher in CD patients compared to UC (baseline
results: median concentrations 1013.73 vs 78.30 ng/mL; P = 0.06 for the Kruskall-Wallis test; results at 6–8
weeks: 1076.48 vs 53.10 ng/mL, P = 0.01).
Fibrosis was clearly present in patients with CD and its severity increased (reflected by both YKL-40/
CHI3L1 and PIIINP concentrations) in 6–8 weeks of follow up, regardless of the treatment used during
that time. In patients with UC the levels of YKL-40/CHI3L1 and PIIINP were lower at baseline and further
decreased after 6–8 weeks (median concentrations were respectively: 39.5 ng/mL vs 24.7 ng/mL and
78.3 ng/mL vs 53.1 ng/mL).
C o n c l u s i o n: Fibrosis was more severe in CD than in UC patients. The marker that more accurately
reflected these differences was PIIINP.
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Introduction
It is generally accepted that location and severity of inflammatory lesions are respon-
sible for different clinical features and course of ulcerative colitis (UC) and Crohn’s
disease (CD). In patients with UC chronic inflammation of intestinal submucosa with
deposition of collagen and development of fibrosis affects superficial layers of mucosa.
In contrast, in patients with CD the inflammatory infiltrate may involve the whole
thickness of intestinal wall with full-thickness collagen deposition and fibrosis leading
to intestinal strictures.
YKL-40/CHI3L1 and PIIINP (N-terminal propeptide, of type III procollagen) may
be useful for monitoring of clinical activity of inflammatory bowel disease (IBD) and
prediction of fibrosis. YKL-40, also referred to as Chitinase 3-like 1 (CHI3L1) is a 40-kD
glycoprotein known from early 1990s, when a radioimmune (RIA) assay measuring
serum levels of YKL-40 was first used and described by Johansen, and its biological
significance became better understood [1]. Although the role of YKL-40/CHI3L1 is
still not fully established, its activity has been reported in many diseases, particularly
those associated with inflammation and/or fibrosis. According to reports by Koutrou-
bakis and Vind published in 2003 [2, 3] patients with IBD have higher serum levels of
YKL-40/CHI3L1 than healthy subjects, and the levels correlate with clinical severity of
the disease. Similar conclusions were drawn from preliminary studies of patients with
CD. No data assessing the levels of these factors in children are available, except for
one report by Wewer [4]. The role of PIIINP, both its metabolites and enzymes
involved in its synthesis and degradation, in pathogenesis of IBD is not fully under-
stood, although it is known that PIIINP activity is significantly higher in patients with
UC. The relevance of PIIINP in pediatric IBD is also not known.
The aim of the study was to assess the usefulness of measurements of serum levels
of YKL-40/CHI3L1 and PIIINP as biochemical markers of severity of intestinal fi-
brosis associated with inflammation in patients with IBD during first 8-weeks of
treatment. Another aim of the study was to reveal the differences in the dynamics
of fibrosis between UC and CD patients.
Patients and Methods
To this prospective controlled study we enrolled newly diagnosed patients with IBD,
who fulfilled following inclusion criteria:
1. Age ≤18 years.
2. Children with IBD diagnosis confirmed by clinical features, endoscopic and
histological examination.
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3. Patients with a first episode of IBD with local and systemic manifestations (abdominal
pain, diarrhea, blood in stools, fever, malaise).
4. Informed consent given by parents/guardians, as well as by the patient, if aged >16
years.
Control group consisted of 32 healthy children without gastrointestinal and
fibrotic disorders. All participants didn’t met exclusion criteria:
1. Decline to provide informed consent by parents/guardians, as well as by the patient, if
aged >16 years.
2. Serious comorbidities (eg. pneumonia or other serious inflammatory disorders).
Baseline measurements of the levels of fibrosis factors were performed at the time
of inclusion (i.e. diagnosis) in IBD patients, followed by the assessment at third and
then sixth to eight week of treatment. In children from the control group the mea-
surements were performed only once.
All IBD patients enrolled in the study underwent a standard diagnostic workup. In
the majority of patients this included fecal occult blood test, microbiological exam-
ination of the stool (including pathogenic Eschericha coli [EPEC], Salmonella spp.,
Shigella spp., Clostridium difficile, Campylobacter jejuni, Campylobacter coli, Yersinia
enterocolitica), parasitological examination of the stool (including Giardia intestinalis
antigen) and mycological examination of the stool followed by gastrointestinal endo-
scopy (duodenoesophagoscopy, ileocolonoscopy) and histological examination of
biopsy specimens. Assessment of severity of the disease included clinical manifesta-
tions and complete blood count (CBC), erythrocyte sedimentation rate (ESR) and
serum levels of C-reactive protein (CRP), albumin and total protein.
The baseline data on signs, symptoms and treatment were collected using a dedi-
cated questionnaire for children with IBD.
The study was approved by Medical Ethics Committee of Jagiellonian University
in Cracow decision: No. KBET/6/B/2009 of 29 January 2009.
Biochemical studies
Serum concentrations of YKL-40/CHI3L1 and PIIINP were measured in Clinical
Biochemistry Department, Institute of Paediatrics, Jagiellonian University Medical
College, using ELISA assay (METRA YKL-40 ELISA Kit, Quidel; and PIII-NP ELISA
Kit, Wuhan USC Science ltd).
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Statistics
The levels of YKL-40/CHI3L1 and PIIINP in respective time points were compared
using t-Student test for dependent variables. For comparisons with the control group
the exact Fischer test, t-Student test for independent variables, or Kruskall-Wallis test
were used.
Statistical calculations were performed using IBM SPSS Statistics 21 software. The
level of statistical significance was assumed at the risk of the Type I error below 5%
(α = 0.05).
Sample size was calculated on the basis of literature data stating that mean level of
YKL-40/CHI3L1 in the population of patients with IBD is 90 ng/mL+/–80(SD). The
change of 40 ng/mL during treatment was assumed clinically significant. To document
this difference with 5% probability of Type I error and 80% statistical power, the study
should include at least 60 children, which was achieved.
Results
92 children (48 girls and 44 boys) aged from 2 to 18 years (mean age 12.86 years,
SD ± 4.09, median age 14 years) were enrolled in the study. Clinical characteristics of
the study group is given in Table 1.
Table 1.Characteristics of IBD population. Data given in table were completed at the time of
informed consent.
Patient ID Gender Age Diagnosis PCDAI/ PUCAI Location ofinflammation Medications
CD-1 M 15.5 CD 57.5 L4 AZA, CS
CD-2 M 15 CD 25 L1 5-ASA
CD-3 F 2 CD 30 L2,L4 5-ASA, AZA, CS
CD-4 F 13.5 CD 32.5 L2,L4, p 5-ASA, AZA, CS
CD-5 F 17 CD 15 L3 5-ASA, CS
CD-6 M 12 CD 25 L1 5-ASA, AZA, CS
CD-7 F 10 CD 25 L3 5-ASA, AZA, CS
CD-8 F 8 CD 35 L3, L4 5-ASA, CS
CD-9 M 12.5 CD 10 L3, p 5-ASA, AZA, CS
CD-10 M 14 CD 10 L1 5-ASA
CD-11 M 16 CD 22.5 L3, p 5-ASA, AZA
CD-12 M 6 CD 30 L2, L4 5-ASA, AZA, CS
CD-13 M 14 CD 5 L3, p AZA
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Patient ID Gender Age Diagnosis PCDAI/ PUCAI Location ofinflammation Medications
CD-14 M 8 CD 20 L1, L4 5-ASA
CD-15 F 16 CD 5 L3 5-ASA, AZA
CD-16 F 18 CD 40 L3, L4, p 5-ASA, IFX, CS
CD-17 F 16 CD 45 L3 5-ASA
CD-18 F 17 CD 30 L3 5-ASA, AZA, CS
CD-19 M 13 CD 32.5 L3 5-ASA, AZA, CS
CD-20 M 10 CD 17.5 L3 5-ASA, AZA, CS
CD-21 F 15 CD 5 L1 5-ASA, AZA
CD-22 F 17 CD 57.5 L3 5-ASA, CS
CD-23 M 4 CD 15 L1 5-ASA
CD-24 F 16 CD 25 L3, L4 5-ASA, AZA, CS
CD-25 M 12 CD 80 L3, L4 5-ASA, AZA, CS,IFX
CD-26 F 12 CD 62.5 L1 5-ASA, AZA, CS
CD-27 M 12 CD 45 L3 5-ASA, AZA, CS
CD-28 F 10 CD 32.5 L3 5-ASA, AZA, CS
CD-29 M 14 CD 52.5 L2 5-ASA, AZA, IFX
CD-30 M 15 CD 45 L3, L4, p 5-ASA, AZA
CD-31 F 16 CD 37.5 L1 5-ASA, AZA
CD-32 F 16 CD 40 L3, L4 5-ASA, AZA
CD-33 M 9 CD 27.5 L3 5-ASA, AZA, CS
CD-34 M 15 CD 60 L3, L4 5-ASA, AZA, CS,IFX
CD-35 M 7 CD 37.5 L1 5-ASA, AZA, CS
CD-36 M 9 CD 25 L3 5-ASA
CD-37 M 10 CD 15 L3 5-ASA, AZA, CS
CD-38 M 17 CD 30 L1 5-ASA, AZA, CS
CD-39 F 12 CD 22.5 L2, p 5-ASA, AZA, CS
CD-40 F 6 CD 25 L1 5-ASA
CD-41 F 17 CD 50 L3, L4, p 5-ASA, AZA, CS
UC-1 F 16 UC 60 LC 5-ASA
Table 1.Cont.
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There were no statistically significant differences in sex and age between the study
groups (median age of patients with CD and UC was 14 years, and median age of
controls was 14.5 years; P value = 0.75 in Kruskall-Wallis ANOVA test). The study
population included 41 (44.56%) children with CD, 19 (20.65%) children with UC,
and 32 (34.78%) controls. Half of UC patients presented with pancolitis and clinical
activity of illness assessed according to PUCAI (Pediatric Ulcerative Colitis Activity
Index) ranged from 10 to 65 points (mean 33.5, SD ± 14.61). Patients with CD had
various types of the disease, including perianal lesions (n = 8), inflammatory lesions of
varied locations, and lesions causing clinically irrelevant strictures (n = 3). The clinical
activity of illness assessed according to PCDAI (Pediatric Crohn Disease Activity
Patient ID Gender Age Diagnosis PCDAI/ PUCAI Location ofinflammation Medications
UC-2 F 12 UC 10 PC 5-ASA
UC-3 M 17 UC 10 PC 5-ASA
UC-4 F 9 UC 40 PC 5-ASA, CS
UC-5 M 12 UC 35 PC 5-ASA, CS
UC-6 F 18 UC 30 PC 5-ASA, CS
UC-7 F 16 UC 45 LC 5-ASA
UC-8 F 17 UC 40 PC 5-ASA
UC-9 M 13 UC 40 LC 5-ASA, CS
UC-10 F 12 UC 30 LC 5-ASA, CS
UC-11 F 16 UC 20 LC 5-ASA, CS
UC-12 F 12 UC 10 LC 5-ASA, CS
UC-13 M 7 UC 25 LC 5-ASA
UC-14 F 15.5 UC 40 PC 5-ASA
UC-15 F 16 UC 40 PC 5-ASA, CS, AZA,IFX
UC-16 F 18 UC 30 LC 5-ASA
UC-17 M 17 UC 30 PC 5-ASA, CS
UC-18 F 13 UC 65 LC 5-ASA, CS
UC-19 F 17 UC 40 LC 5-ASA
CD — Crohn’s disease, UC — ulcerative colitis, L1 — distal 1/3 ileum ± limited cecal disease, L2 — colonic,
L3 — ileocolonic, L4 — upper disease, p — perianal disease, PC — pancolitis, LC — left side colitis, 5-ASA —
5-aminosalicylic acid, AZA — azathioprine, CS — corticosteroids, IFX — infliximab.
Table 1.Cont.
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Index) ranged from 5 to 57.5 points (mean 30.7, SD ± 17.38). None of the patients
required surgical intervention during study period.
Assessment of biochemical markers of fibrosis in respective periods revealed sig-
nificant differences between the study groups (Table 2). 19 patients at week 3rd and 11
at weeks 6th to 8th were lost to follow up because they did not volunteer for follow-up
visits at particular periods of time.
PIIINP levels were significantly higher in children with CD than in children with
UC (median levels at baseline were 1013.73 ng/mL vs 78.30 ng/mL, respectively;
P value = 0.06 in Kruskall-Wallis ANOVA test; median levels after 6–8 weeks of
treatment were 1076.48 ng/mL vs 53.10 ng/mL, respectively; P value = 0.01).
When levels of YKL-40/CHI3L1 were compared in patients with CD and patients
with UC, no significant differences were found. YKL-40/CHI3L1 levels slightly
increased in CD patients (from 34.56 ng/ml to 40.30 ng/ml) and decreased in UC
patients (from 39.50 ng/ml to 24.70 ng/ml) (see Fig. 1A and Fig. 1B).
Table 2.Concentration of YKL40 and PIIINP (ng/mL).
Study groups
Crohn’s disease Ulcerative colitis Control Correlations
N Median QRange N Median QRange N Median QRange p
YKL at 0 41 34.56 40.21 19 39.50 30.60 32 36.30 27.89 0.96
YKL at
14-21 day 28 37.05 36.28 13 30.50 36.77 0 — — 0.85
YKL at
6-8 week 19 40.30 45.07 11 24.70 43.81 0 — — 0.68
PIIINP at 0 41 1013.73 1997.88 19 78.30 723.80 32 399.38 940.29 0.06
PIIINP at
14-21 day 28 748.72 1855.46 13 124.50 411.50 0 — — 0.37
PIIINP at
6-8 week 19 1076.48 1509.80 11 53.10 675.45 0 — — 0.01
YKL-40/CHI3L1 — a 40-kilodalton glycoprotein also referred to as chitinase 3 like-1 — CHI3L1, PIIINP — N-terminal
propeptide of type III procollagen
Serum concentrations of fibrosis markers in children with inflammatory bowel disease 67
Fig. 1A. Distribution of YKL40 (ng/mL) in patient with CD and UC. Comparison of groups. YKL-40/
CHI3L1 — a 40-kilodalton glycoprotein also referred to as chitinase 3 like-1 — CHI3L1.
Fig. 1B. Distribution of PIIINP (ng/mL) in patient with CD and UC. Comparison of groups. PIIINP —
N-terminal propeptide of type III procollagen.
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Discussion
IBD is a group of diseases of still unclear etiology associated with activation of in-
testinal immune system as a result of abnormal interactions between the host and its
microbiome. CD and UC differ with locations of lesions and depth of inflammatory
infiltrate. In patients with UC the inflammatory infiltrate causes remodeling of super-
ficial layers of mucosa, while in patients with CD it leads to full-thickness remodeling
of the intestinal wall. Fibrosis is a nonspecific response to inflammation. In patients
with UC it is limited to intestinal mucosa, while in patients with CD it affects the
whole thickness of intestinal wall and leads to intestinal strictures. Fibrosis is closely
related to mucosal repair [5–7]. Inflammatory response cells (monocytes, neutrophils)
remove the damaged tissues and at the same time produce active immune response
factors, such as interleukins (IL), mainly IL-1, IL-6 and tumor necrosis factor (TNF)
alpha, that activate fibroblasts and thus initiate mucosal repair processes (reepitheli-
zation) such as angiogenesis, fibrogenesis and lymphogenesis. Reepithelization is as-
sociated with accumulation of extracellular matrix (ECM) composed mainly of me-
senchymal cells (Mcs), including fibroblasts and myofibroblasts. There are several
hypotheses on the role of fibrosis in IBD [8–12]. Some of them assume that excessive
deposition of ECM is related to tissue remodeling and may lead to tissue fibrosis;
moreover it is hypothesized that collagen metabolism is increased both in CD as in
inflamed tissue in UC [13, 14]. Data related to the changes in PIIINP level, the
propeptide that takes part in intestinal fibrosis and in the turnover of the key ECM
components – type I and type III collagen – are inconsistent in patients with CD [15–17].
In Wu et al. study it has been established that PIIINP (key component of ECM) can
help in determining risk of uncomplicated inflammatory disease converting to stric-
turing in children with CD. In this study, ECM has been identified as a predictive
factor of fibrostenotic complications in patients with CD [18].
A study by Sazouk revealed that in the early inflammatory phase fibrocytes differ-
entiate to fibroblasts, which take part in early fibrosis and increase inflammation by
production of TNF alpha [19]. Therefore, it is important to establish whether anti-
inflammatory treatment may stop these adverse outcomes related to tissue remodeling
and prevent fibrosis. YKL-40/CHI3L1 is a glycoprotein produced by activated macro-
phages and neutrophils during inflammation; it is also produced by chondrocytes and
synovial cells. YKL-40/CHI3L1 is a growth factor stimulating fibroblasts and endothe-
lial cells (fibrogenesis, angiogenesis). YKL-40/CHI3L1 is one of chitinases binding
chitin and heparin, and therefore it is currently more commonly known under the
name of CHI3L1. Chitinases are enzymes generally typical for organisms that produce
chitin, such as insects, fish, shellfish, and other marine organisms, and not for mam-
mals.
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Although the last ones do not produce chitin, they may periodically or con-
stantly produce chitinases, which role in mammals is still unclear. It is thought
that YKL-40/CHI3L1 is produced by healthy humans. However, it is present in
the case of numerous inflammatory conditions, including rheumatoid arthritis or
hepatitis, as well as in neoplasms, such as colorectal cancer. In patients with IBD
YKL-40/CHI3L1 is present in macrophages of epithelium and lamina propria [20].
YKL is released by activated macrophages and neutrophils and promotes myofibro-
blast-induced collagen secretion [21]. YKL-40/CHI3L1 and other chitinases pro-
duced by mammals play a key role in the pathogenesis of IBD, asthma and other
inflammatory diseases. Chitinases are a very important factor in the innate immune
response against intestinal microorganisms. Their abnormal overproduction may
paradoxically stimulate chronic inflammation.
Our study revealed that during 6–8-week course of treatment with 5-ASA and/or
corticosteroids and/or azathioprine patients with CD and UC presented with different
levels of YKL-40/CHI3L1 and PIIINP. Fibrosis was more pronounced in patients with
CD and demonstrated by an increasing trend for both YKL-40/CHI3L1 and PIIINP
during 6–8-week follow-up regardless of the treatment administered during this time.
The patterns of YKL-40/CHI3L1 and PIIINP levels in patients with UC were different,
with lower absolute values and levels decreasing in the course of treatment.
It is difficult to compare our data with those of other authors, because of very
limited number of studies investigating this issue in children [4]. Aomatsu et al. find
out fecal CHI3L1 as a useful marker that helps to differentiate between IBD and
healthy controls with specificity and sensitivity over 80%. Similarly as in our study
levels of CHI3L1 were higher in CD compared to UC patients. Basing on study results
authors concluded that fecal CHI3L1 can be used as a predictor of severity and activity
of the illness [22]. In adult patients results of serum concentration of YKL-40/CHI3L1
are conflicting as fare as its correlation with disease activity is concerned [2, 3, 23].
Alike in our study Vind et al. demonstrate that in patients with UC, YKL-40/CHI3L1
diminish during treatment, while in Crohn’s patients values are higher and remind
elevated also in inactive individuals. In our patients with CD levels of PIIINP were
elevated independently on the pharmacological treatment. De Simone et al. observed
significant reduction in PIIINP levels after 6 month after surgical intervention [24].
Substantial data indicate that treatment used in patients with IBD does not pre-
vent fibrosis. Cytokines and growth factors (TGF-beta, IGF-1, GF-1) released by
macrophages, lymphocytes, mast cells or mesenchymal cells contribute to fibrosis
by the synthesis of ECM, proliferation of mesenchymal (fibrogenous) cells and there-
fore, according to the opinion of Lund, no effective anti-fibrotic treatment of IBD is
currently available [15, 25].
Ineffectiveness of treatment may be associated with crossing the point of no
return, where fibrosis cannot be stopped by anti-inflammatory, immunomodulating
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or biological treatment [26]. Some reports indicated that immunosuppressive treat-
ment in patients with risk factors of fibrosis does not lead to significant reduction in
the development of strictures [27]. In clinical practice, levels of PIIINP and YKL-40/
CHI3L1 are not routinely measured. Moreover, no recommendations on their use in
the diagnostics or unequivocal statements on their usefulness are available, and their
sensitivity and specificity is not known [28].
From a practical point of view it is important to establish whether a stricture found
in a patient with CD is inflammatory (this is associated with a greater chance of
resolution during effective treatment) or fibrotic (in such case no effective drugs
are available) [29]. Even the effectiveness of the promising biological anti-TNF alpha
therapy is probably limited to the former group of patients [30]. PIIINP is a routinely
used prognostic factor of liver fibrosis, and it is also useful in chronic cardiovascular
diseases associated with fibrosis (hypertension), chronic fibrotic skin diseases or pul-
monary diseases, and other conditions [31–33]. The use of PIIINP in adult patients
with IBD is controversial because of a chronic course of the disease and high risk of
comorbidities that may also be associated with fibrosis. On the contrary, in the case of
IBD in young patients with no comorbidities the usefulness of this marker is higher.
We attempted to answer the question, whether in children with IBD, YKL-40/CHI3L1
and PIIINP may be used as serological biomarkers allowing for prediction of strictures
and monitoring of the outcomes of treatment.
Undoubtedly, among the limitations of our study, we should mention the uneven
size of the studied groups, variations in location and clinical activity within both
groups of patients, and the loss of a significant number of patients in follow-up.
Our study including in the final analysis 60 children with IBD allows for drawing
preliminary conclusions and suggesting future research. Because of a limited sample
size our results are of general character and may be used to indicate further directions
for research that would include a baseline type of the disease, its severity, type of
treatment and its results.
Conclusions
Fibrosis is more pronounced in patients with CD compared to those with UC. PIIINP
reflects these differences significantly better than YKL-40/CHI3L1. Further research is
necessary to assess long-term perspective of fibrosis in patients with CD, as well
as possible differences depending on the type and severity of the disease, and the
treatment used.
In patients with UC fibrosis seems to have low intensity and reveal a tendency to
resolution over several weeks of treatment. It must still be proven that including YKL-
40/CHI3L1 and PIIINP in the diagnostics of IBD may be useful in equivocal cases that
are an important problem in pediatric patient population.
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